Kineret — Cigna
Castleman Disease (multicentric, relapsed or refractory)
Initial criteria
- Patient is age ≥ 18 years; AND
- Medication is being used for multicentric disease that is relapsed or refractory; AND
- Medication is prescribed by or in consultation with an oncologist or hematologist
Reauthorization criteria
- Patient has been established on therapy for at least 6 months; AND
- Patient meets at least ONE of the following: (a) Beneficial clinical response from baseline assessed by objective measure; OR (b) Improvement in at least one symptom
Approval duration
initial 6 months; reauth 1 year